} 2 4 -m o n t h m u l t i c e n t e r, r a n d o m i z e d , comparative, double-blind, double-dummy, controlled study (n=194 patients).
TREATMENT REGIMEN --------------------------------------------------------------------------------------------------
} 1200 mg of chondroitin sulphate daily (Condrosan, Bioibérica) or 200 mg of celecoxib daily (Celebrex, Pfizer).
} Acetaminophen maximum 3 g/day allowed as rescue medication.
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} To explore the DMOAD effect of chondroitin sulphate treatment vs celecoxib on cartilage volume loss in k n e e O A a f t e r 2 4 m o n t h s b y quantitative Magnetic Resonance Imaging (qMRI). } Signs of synovitis (warmth, swelling or effusion).
MAIN OBJECTIVE
} Minimum joint space width ≥ 2 mm in the medial femorotibial compartment on standing knee X-ray.
} Knee pain for the last month and a VAS of pain while walking ≥ 40 mm.
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MAIN EXCLUSION CRITERIA (II)
} Subjects with a history of heart attack or stroke, heart disease, or congestive heart failure (functional classes II-IV of the NYHA).
} Subjects with high risk of CV events.
} Subjects with chronic liver or kidney disease.
} Subjects with a history of recurrent UGI ulceration or active inflammatory bowel disease.
} Subjects treated for oesophageal, gastric, pyloric channel, or duodenal ulceration. 
STATISTICAL METHODS
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} The study outcomes were assessed using the completer population. In addition, the ITT-LOCF (ANCOVA) population was used to assess the primary outcome and cartilage volume loss (CVL) global and medial compartments. 
PAIN (VAS) (cm)
Mean (SD)
6.2 ± 1.6 5.9 ± 1.8 6.1 ± 1.7 
WOMAC
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*ANCOVA (age, gender, BMI, meniscal lesions) Completers (p=0.05) 
CARTILAGE VOLUME LOSS Lateral Compartment
Cartilage volume loss (%) Lateral compartment 
SAFETY RESULTS
} No differences in the safety profile were detected.
} Patients with high CV or GI risk were excluded (according to Celebrex SmPC).
} In general, AEs were mild and evenly distributed among treatment groups.
